214 related articles for article (PubMed ID: 37973660)
1. Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T cell exhaustion.
Wahid M; Pratoomthai B; Egbuniwe IU; Evans HR; Babaei-Jadidi R; Amartey JO; Erdelyi V; Yacqub-Usman K; Jackson AM; Morris JC; Patel PM; Bates DO
Cancer Immunol Immunother; 2023 Dec; 72(12):4001-4014. PubMed ID: 37973660
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis.
Supradit K; Boonsri B; Duangdara J; Thitiphatphuvanon T; Suriyonplengsaeng C; Kangsamaksin T; Janvilisri T; Tohtong R; Yacqub-Usman K; Grabowska AM; Bates DO; Wongprasert K
Toxicol In Vitro; 2022 Aug; 82():105385. PubMed ID: 35568131
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylation of SRSF1 by SRPK1 regulates alternative splicing of tumor-related Rac1b in colorectal cells.
Gonçalves V; Henriques AF; Pereira JF; Neves Costa A; Moyer MP; Moita LF; Gama-Carvalho M; Matos P; Jordan P
RNA; 2014 Apr; 20(4):474-82. PubMed ID: 24550521
[TBL] [Abstract][Full Text] [Related]
4. Splicing kinase SRPK1 conforms to the landscape of its SR protein substrate.
Aubol BE; Jamros MA; McGlone ML; Adams JA
Biochemistry; 2013 Oct; 52(43):7595-605. PubMed ID: 24074032
[TBL] [Abstract][Full Text] [Related]
5. SRPK1/2 and PP1α exert opposite functions by modulating SRSF1-guided MKNK2 alternative splicing in colon adenocarcinoma.
Liu H; Gong Z; Li K; Zhang Q; Xu Z; Xu Y
J Exp Clin Cancer Res; 2021 Feb; 40(1):75. PubMed ID: 33602301
[TBL] [Abstract][Full Text] [Related]
6. Altered VEGF Splicing Isoform Balance in Tumor Endothelium Involves Activation of Splicing Factors Srpk1 and Srsf1 by the Wilms' Tumor Suppressor Wt1.
Wagner KD; El Maï M; Ladomery M; Belali T; Leccia N; Michiels JF; Wagner N
Cells; 2019 Jan; 8(1):. PubMed ID: 30641926
[TBL] [Abstract][Full Text] [Related]
7. An Extended PD-L2 Cytoplasmic Domain Results From Alternative Splicing in NSCLC Cells.
Dietz LL; Furman NT; Larsen TV; Daugaard TF; Thomsen EA; Keller JL; Aagaard L; Sorensen BS; Nielsen AL
J Immunother; 2022 Nov-Dec 01; 45(9):379-388. PubMed ID: 36036966
[TBL] [Abstract][Full Text] [Related]
8. Serine and arginine rich splicing factor 1 deficiency alters pathways involved in IL-17A expression and is implicated in human psoriasis.
Su S; Katopodi XL; Pita-Juarez YH; Maverakis E; Vlachos IS; Adamopoulos IE
Clin Immunol; 2022 Jul; 240():109041. PubMed ID: 35613697
[TBL] [Abstract][Full Text] [Related]
9. Alternative splicing of SLC39A14 in colorectal cancer is regulated by the Wnt pathway.
Thorsen K; Mansilla F; Schepeler T; Øster B; Rasmussen MH; Dyrskjøt L; Karni R; Akerman M; Krainer AR; Laurberg S; Andersen CL; Ørntoft TF
Mol Cell Proteomics; 2011 Jan; 10(1):M110.002998. PubMed ID: 20938052
[TBL] [Abstract][Full Text] [Related]
10. Molecular interactions connecting the function of the serine-arginine-rich protein SRSF1 to protein phosphatase 1.
Aubol BE; Serrano P; Fattet L; Wüthrich K; Adams JA
J Biol Chem; 2018 Oct; 293(43):16751-16760. PubMed ID: 30185622
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus type 16 infection activates the host serine arginine protein kinase 1 (SRPK1) - splicing factor axis.
Mole S; Faizo AAA; Hernandez-Lopez H; Griffiths M; Stevenson A; Roberts S; Graham SV
J Gen Virol; 2020 May; 101(5):523-532. PubMed ID: 32182205
[TBL] [Abstract][Full Text] [Related]
12. An anti-PD-1 antisense oligonucleotide promotes the expression of soluble PD-1 by blocking the interaction between SRSF3 and an exonic splicing enhancer of PD-1 exon 3.
Wang X; Yan L; Guo J; Jia R
Int Immunopharmacol; 2024 Jan; 126():111280. PubMed ID: 38043270
[TBL] [Abstract][Full Text] [Related]
13. Intra-domain Cross-talk Regulates Serine-arginine Protein Kinase 1-dependent Phosphorylation and Splicing Function of Transformer 2β1.
Jamros MA; Aubol BE; Keshwani MM; Zhang Z; Stamm S; Adams JA
J Biol Chem; 2015 Jul; 290(28):17269-81. PubMed ID: 26013829
[TBL] [Abstract][Full Text] [Related]
14. Molecular Mechanism of SR Protein Kinase 1 Inhibition by the Herpes Virus Protein ICP27.
Tunnicliffe RB; Hu WK; Wu MY; Levy C; Mould AP; McKenzie EA; Sandri-Goldin RM; Golovanov AP
mBio; 2019 Oct; 10(5):. PubMed ID: 31641093
[TBL] [Abstract][Full Text] [Related]
15. Serine-arginine-rich protein kinase-1 inhibition for the treatment of diabetic retinopathy.
Malhi NK; Allen CL; Stewart E; Horton KL; Riu F; Batson J; Amoaku W; Morris JC; Arkill KP; Bates DO
Am J Physiol Heart Circ Physiol; 2022 Jun; 322(6):H1014-H1027. PubMed ID: 35302878
[TBL] [Abstract][Full Text] [Related]
16. The control of alternative splicing by SRSF1 in myelinated afferents contributes to the development of neuropathic pain.
Hulse RP; Drake RA; Bates DO; Donaldson LF
Neurobiol Dis; 2016 Dec; 96():186-200. PubMed ID: 27616424
[TBL] [Abstract][Full Text] [Related]
17. Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma.
Gammons MV; Lucas R; Dean R; Coupland SE; Oltean S; Bates DO
Br J Cancer; 2014 Jul; 111(3):477-85. PubMed ID: 25010863
[TBL] [Abstract][Full Text] [Related]
18. Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer.
Mavrou A; Brakspear K; Hamdollah-Zadeh M; Damodaran G; Babaei-Jadidi R; Oxley J; Gillatt DA; Ladomery MR; Harper SJ; Bates DO; Oltean S
Oncogene; 2015 Aug; 34(33):4311-9. PubMed ID: 25381816
[TBL] [Abstract][Full Text] [Related]
19. SRPK1 and Clk/Sty protein kinases show distinct substrate specificities for serine/arginine-rich splicing factors.
Colwill K; Feng LL; Yeakley JM; Gish GD; Cáceres JF; Pawson T; Fu XD
J Biol Chem; 1996 Oct; 271(40):24569-75. PubMed ID: 8798720
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
